Drug Trial Radar · NCT05186285
Single Ascending Dose Study of CM338 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Dec 11, 2021
Primary completion
Jul 27, 2022
Study completion Jul 27, 2022
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was a single-center, randomized, double blind, placebo-controlled, single-dose, dose-increasing study to evaluate the safety, tolerability, PK characteristics, PD effect, and immunogenicity of CM338 injection administered intravenously or subcutaneously at different doses in healthy subjects.
Conditions
- Healthy
Interventions
CM338Drug
CM338 : a humanized monoclonal antibody.
PlaceboDrug
Placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety : Incidence of Adverse Events (AEs).Time frame: Baseline up to Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PKUCare Luzhong Hospital
Zibo, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.